PI-103 Hydrochloride
Based on 33 publication(s) in Google Scholar
PI-103 Hydrochloride is a dual PI3K and mTOR inhibitor with IC50s of 8 nM, 88 nM, 48 nM, 150 nM, 20 nM, and 83 nM for p110α, p110β, p110δ, p110γ, mTORC1, and mTORC2. PI-103 Hydrochloride also inhibits DNA-PK with an IC50 of 2 nM. PI-103 Hydrochloride induces autophagy.
For research use only. We do not sell to patients.
- Purity: 98.06%
- CAS No.: 371935-79-4
- Formula: C19H17ClN4O3
- Molecular Weight:384.82
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications Citing Use of MedChemExpress (MCE) PI-103 Hydrochloride
More- Adv Funct Mater. 2021 May 24.
- Mol Cell. 2025 Mar 19:S1097-2765(25)00186-8. [Abstract]
- Nat Commun. 2025 May 15;16(1):4502. [Abstract]
- Nat Commun. 2023 Mar 28;14(1):1726. [Abstract]
- Adv Sci (Weinh). 2026 Mar;13(13):e15546. [Abstract]
- Clin Cancer Res. 2020 Apr 15;26(8):2011-2021. [Abstract]
- Clin Cancer Res. 2014 Nov 1;20(21):5483-95. [Abstract]
- Cancer Lett. 2025 Apr 28:616:217532. [Abstract]
- Adv Healthc Mater. 2022 May;11(9):e2101944. [Abstract]
- Acta Biomater. 2021 Aug:130:409-422. [Abstract]
- Cell Syst. 2025 Mar 19;16(3):101203. [Abstract]
- Cell Syst. 2020 Jan 22;10(1):66-81.e11. [Abstract]
- J Transl Med. 2021 Dec 7;19(1):497. [Abstract]
- Oncogenesis. 2025 Mar 1;14(1):4. [Abstract]
- Biochem Pharmacol. 2026 Mar 15:249:117903. [Abstract]
- Front Pharmacol. 2020 Nov 11;11:580407. [Abstract]
- Molecules. 2020 Apr 23;25(8):1980. [Abstract]
- cell rep methods. 2022 Jan 24;2(2):100155. [Abstract]
- Antimicrob Agents Chemother. 2020 Sep 21;64(10):e00608-20. [Abstract]
- J Virol. 2022 Dec 14;96(23):e0145322. [Abstract]
- Cell Signal. 2024 Jun:118:111126. [Abstract]
- Heliyon. 2024 May 7;10(9):e30833. [Abstract]
- BMC Cancer. 2022 Nov 24;22(1):1211. [Abstract]
- ChemMedChem. 2019 Nov 20;14(22):1933-1939. [Abstract]
- FEBS Lett. 2026 Jun 8. [Abstract]
- Am J Cancer Res. 2025 May 15;15(5):2097-2110. [Abstract]
- Expert Rev Anticancer Ther. 2024 Sep 10:1-12. [Abstract]
- Exp Eye Res. 2018 Jul:172:10-20. [Abstract]
- bioRxiv. 2026 May 20.
- bioRxiv. 2025 Oct 31.
- Princeton University. 2025.
- bioRxiv. 2024 May 31:2024.05.30.596676. [Abstract]
- Research Square Preprint. 2022 Jul.
Biological Activity
|
p110α 2 nM (IC50) |
p110β 3 nM (IC50) |
p110δ 3 nM (IC50) |
p110γ 15 nM (IC50) |
mTORC1 20 nM (IC50) |
mTORC2 83 nM (IC50) |
DNA-PK 23 nM (IC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A-375 | IC50 |
0.33 μM
Compound: 10e
|
Antiproliferative activity against A375 cells
Antiproliferative activity against A375 cells
|
[PMID: 17339109] |
| A549 | IC50 |
0.54 μM
Compound: 10e
|
Antiproliferative activity against human A549 cells
Antiproliferative activity against human A549 cells
|
[PMID: 17339109] |
| HeLa | IC50 |
0.54 μM
Compound: 10e
|
Antiproliferative activity against human HeLa cells
Antiproliferative activity against human HeLa cells
|
[PMID: 17339109] |
| MCF7 | IC50 |
0.13 μM
Compound: 10e
|
Antiproliferative activity against adriamycin-resistant MCF7 cells
Antiproliferative activity against adriamycin-resistant MCF7 cells
|
[PMID: 17339109] |
| MCF7 | IC50 |
0.18 μM
Compound: 10e
|
Antiproliferative activity against human MCF7 cells
Antiproliferative activity against human MCF7 cells
|
[PMID: 17339109] |
| Sf9 | IC50 |
0.003 μM
Compound: 2
|
Inhibition of GST-tagged human p110-beta expressed in SF9/Baculovirus system by SPA
Inhibition of GST-tagged human p110-beta expressed in SF9/Baculovirus system by SPA
|
[PMID: 17601739] |
| Sf9 | IC50 |
0.0036 μM
Compound: 2
|
Inhibition of GST-tagged bovine p110-alpha expressed in SF9/Baculovirus system by SPA
Inhibition of GST-tagged bovine p110-alpha expressed in SF9/Baculovirus system by SPA
|
[PMID: 17601739] |
| Sf9 | IC50 |
0.01 μM
Compound: 2
|
Inhibition of glu-tagged PI3K C2-beta expressed in SF9/Baculovirus system by SPA
Inhibition of glu-tagged PI3K C2-beta expressed in SF9/Baculovirus system by SPA
|
[PMID: 17601739] |
| Sf9 | IC50 |
0.25 μM
Compound: 2
|
Inhibition of His-tagged human p110gamma expressed in SF9/Baculovirus system by SPA
Inhibition of His-tagged human p110gamma expressed in SF9/Baculovirus system by SPA
|
[PMID: 17601739] |
PI-103 exhibits antiproliferative properties in a panel of human cancer cell lines[1]. PI-103 is essentially cytostatic for cell lines and induced cell cycle arrest in the G1 phase. In blast cells, PI-103 inhibits leukemic proliferation, the clonogenicity of leukemic progenitors and induces mitochondrial apoptosis, especially in the compartment containing leukemic stem cells [2]. PI-103 potently inhibits both the rapamycin-sensitive (mTORC1, IC50=20 nM) and rapamycin-insensitive (mTORC2, IC50=83 nM) complexes of the protein kinase mTOR[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 371935-79-4
-
Appearance Solid
-
Molecular Weight 384.82
-
Formula C19H17ClN4O3
-
Color Off-white to yellow
-
SMILES
OC1=CC(C2=NC3=C(OC4=C3C=CC=N4)C(N5CCOCC5)=N2)=CC=C1.[H]Cl
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (33)
-
Journal Impact Factor
-
Most Recent
-
-
Mol Cell
PI3Kβ functions as a protein kinase to promote cellular protein O-GlcNAcylation and acetyl-CoA production for tumor growth. [Abstract]2025 Mar 19:S1097-2765(25)00186-8. PMID: 40132583 -
Nat Commun
TIGIT deficiency promotes autoreactive CD4+ T-cell responses through a metabolic‒epigenetic mechanism in autoimmune myositis. [Abstract]2025 May 15;16(1):4502. PMID: 40374622 -
Nat Commun
Domain-specific p53 mutants activate EGFR by distinct mechanisms exposing tissue-independent therapeutic vulnerabilities. [Abstract]2023 Mar 28;14(1):1726. PMID: 36977662 -
Adv Sci (Weinh)
EGR Proteins Mediate Interferon-Independent Anti-HSV-1 Responses Through Viral and Host Targets. [Abstract]2026 Mar;13(13):e15546. PMID: 41486724 -
Clin Cancer Res
Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors. [Abstract]2020 Apr 15;26(8):2011-2021. PMID: 31937620 -
Clin Cancer Res
Upregulation of IGF1R by mutant RAS in leukemia and potentiation of RAS signaling inhibitors by small-molecule inhibition of IGF1R. [Abstract]2014 Nov 1;20(21):5483-95. PMID: 25186968 -
Cancer Lett
2025 Apr 28:616:217532. PMID: 40021040 -
Adv Healthc Mater
2022 May;11(9):e2101944. PMID: 34889072 -
Acta Biomater
A general prodrug nanohydrogel platform for reduction-triggered drug activation and treatment of taxane-resistant malignancies. [Abstract]2021 Aug:130:409-422. PMID: 34087447 -
Cell Syst
Large-scale control over collective cell migration using light-activated epidermal growth factor receptors. [Abstract]2025 Mar 19;16(3):101203. PMID: 40037348 -
Cell Syst
Torin2 Exploits Replication and Checkpoint Vulnerabilities to Cause Death of PI3K-Activated Triple-Negative Breast Cancer Cells. [Abstract]2020 Jan 22;10(1):66-81.e11. PMID: 31812693 -
J Transl Med
Delineation of colorectal cancer ligand-receptor interactions and their roles in the tumor microenvironment and prognosis. [Abstract]2021 Dec 7;19(1):497. PMID: 34876143 -
Oncogenesis
STAG2 expression imparts distinct therapeutic vulnerabilities in muscle-invasive bladder cancer cells. [Abstract]2025 Mar 1;14(1):4. PMID: 40025053 -
Biochem Pharmacol
Ticagrelor reverses multidrug resistance in breast cancer by inhibiting PI3K/AKT/mTOR pathway and suppressing ABCB1 expression and function. [Abstract]2026 Mar 15:249:117903. PMID: 41846011 -
Front Pharmacol
CC-223, NSC781406, and BGT226 Exerts a Cytotoxic Effect Against Pancreatic Cancer Cells via mTOR Signaling. [Abstract]2020 Nov 11;11:580407. PMID: 33343350 -
Molecules
In Vitro and in Vivo Activity of mTOR Kinase and PI3K Inhibitors Against Leishmania donovani and Trypanosoma brucei. [Abstract]2020 Apr 23;25(8):1980. PMID: 32340370 -
cell rep methods
2022 Jan 24;2(2):100155. PMID: 35474962 -
Antimicrob Agents Chemother
Inhibitory Effect of PIK-24 on Respiratory Syncytial Virus Entry by Blocking Phosphatidylinositol-3 Kinase Signaling. [Abstract]2020 Sep 21;64(10):e00608-20. PMID: 32718963 -
J Virol
PIK-24 Inhibits RSV-Induced Syncytium Formation via Direct Interaction with the p85α Subunit of PI3K. [Abstract]2022 Dec 14;96(23):e0145322. PMID: 36416586 -
Cell Signal
HK2 promotes migration and invasion of intrahepatic cholangiocarcinoma via enhancing cancer stem-like cells' resistance to anoikis. [Abstract]2024 Jun:118:111126. PMID: 38453126 -
Heliyon
Novel cancer-fighting role of ticagrelor inhibits GTSE1-induced EMT by regulating PI3K/Akt/NF-κB signaling pathway in malignant glioma. [Abstract]2024 May 7;10(9):e30833. PMID: 38774096 -
BMC Cancer
Artificial intelligence to guide precision anticancer therapy with multitargeted kinase inhibitors. [Abstract]2022 Nov 24;22(1):1211. PMID: 36434556 -
ChemMedChem
Oxidative Cyclization-Induced Activation of a Phosphoinositide 3-Kinase Inhibitor for Enhanced Selectivity of Cancer Chemotherapeutics. [Abstract]2019 Nov 20;14(22):1933-1939. PMID: 31696673 -
FEBS Lett
LncRNA YIYA drives pancreatic cancer proliferation under high-glucose conditions by reinforcing a RAS-PKM2-dependent Warburg phenotype. [Abstract]2026 Jun 8. PMID: 42253181 -
Am J Cancer Res
A long-lasting PI3Kδ inhibitor zandelisib forms a water-shielded hydrogen bond with p110δ and demonstrates sustained inhibitory effects. [Abstract]2025 May 15;15(5):2097-2110. PMID: 40520883 -
Expert Rev Anticancer Ther
JARID2 activation by NFYA promotes stemness of triple-negative breast cancer cells through the PI3K/AKT pathway. [Abstract]2024 Sep 10:1-12. PMID: 39254227 -
Exp Eye Res
Expression and regulation of alarmin cytokine IL-1α in human retinal pigment epithelial cells. [Abstract]2018 Jul:172:10-20. PMID: 29551335 -
-
-
-
bioRxiv
Large-scale control over collective cell migration using light-controlled epidermal growth factor receptors. [Abstract]2024 May 31:2024.05.30.596676. PMID: 38853934 -
Solvent & Solubility
DMSO : 4.1 mg/mL (10.65 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocol
IC50 values are measured using either a standard thin-layer chromatography (TLC) assay for lipid kinase activity or a high-throughput membrane capture assay. Kinase reactions are performed by preparing a reaction mixture containing kinase, inhibitor (2% DMSO final concentration), buffer (25 mM HEPES, pH 7.4, 10 mM MgCl2), and freshly sonicated phosphatidylinositol (100 μg/mL). Reactions are initiated by the addition of ATP containing 10 μCi of γ-32P-ATP to a final concentration 10 or 100 μM, and allowed to proceed for 20 minutes at room temperature. For TLC analysis, reactions are then terminated by the addition of 105 μL 1N HCl followed by 160 μL CHCl3:MeOH (1:1). The biphasic mixture is vortexed, briefly centrifuged, and the organic phase transferred to a new tube using a gel loading pipette tip precoated with CHCl3. This extract is spotted on TLC plates and developed for 3-4 hours in a 65:35 solution of n-propanol:1M acetic acid. The TLC plates are then dried, exposed to a phosphorimager screen, and quantitated. For each compound, kinase activity is typically measured at 10-12 inhibitor concentrations representing two-fold dilutions from the highest concentration tested (100 μM). For compounds showing significant activity, IC50 determinations are repeated two to four times, and the reported value is the average of these independent measurements[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
For proliferation assays, MOLM14, OCI-AmL3 and MV4-11 cells are cultured during 48 h at 105 cells/mL, in triplicate, in 10% FCS, without or with 0.1 or 1 μM PI-103, and then pulsed 6 h with 1μCi (37 kBq) [3H]-thymidine. The amounts of radioactivity are determined after trichloracetic acid precipitation[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Mice[3]
Five to six month old males of either FVB/N strain or nude BALB/c strain are injected subcutaneously with one million cells in PBS. When tumor reaches between 50 and 100 mm3, mice are treated with 10 mg/kg or 70 mg/kg of PI-103 and/or 50 mg/kg sorafenib by IP injection daily. Control mice are treated with the same volume of DMSO. Tumor size and mice weight is monitored every 2 days. When mice are sacrificed, tumors are dissected and processed[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (287 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Raynaud FI, et al. Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103through PI-540, PI-620 to the oral agent GDC-0941. Mol Cancer Ther. 2009 Jul;8(7):1725-38. [Content Brief]
[2]. Knight ZA, et al. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell. 2006 May 19;125(4):733-47. [Content Brief]
[3]. Park S, et al. PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase anLeukemia. 2008 Sep;22(9):1698-706.d mTOR, has antileukemicactivity in AmL. Leukemia. 2008 Sep;22(9):1698-706. [Content Brief]
[4]. López-Fauqued M, et al. The dual PI3K/mTOR inhibitor PI-103 promotes immunosuppression, in vivo tumor growth and increases survival of sorafenib-treated melanoma cells. Int J Cancer. 2010 Apr 1;126(7):1549-61. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.5986 mL | 12.9931 mL | 25.9862 mL | 64.9654 mL |
| 5 mM | 0.5197 mL | 2.5986 mL | 5.1972 mL | 12.9931 mL | |
| 10 mM | 0.2599 mL | 1.2993 mL | 2.5986 mL | 6.4965 mL |